Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Excitotoxicity-targeted drugs show neuroprotection in animal models of cerebral ischemia but require early administration.
• Clinical trials confirm limited efficacy for excitotoxicity interventions initiated hours after ischemia.
• Mitochondrial dysfunction is a late event in ischemic neuronal death, presenting a therapeutic target for delayed intervention.

Purpose of the Study:

• To investigate mitochondrial dysfunction as a therapeutic target for delayed neuroprotection after cerebral ischemia.
• To evaluate the potential of ketone bodies to fuel mitochondrial metabolism and prevent delayed neuronal death.

Main Methods:

• Focus on mitochondrial dysfunction and poly(ADP-ribose) polymerase-1 (PARP-1) activation in ischemic neuronal death.
• Exploration of how PARP-1 activation leads to mitochondrial depolarization and NAD+ depletion.
• Assessment of ketone bodies (pyruvate, beta-hydroxybutyrate, gamma-hydroxybutyrate, 1,4-butanediol) as metabolic substrates for functional mitochondria.

Main Results:

• Poly(ADP-ribose) polymerase-1 (PARP-1) activation is a key driver of mitochondrial depolarization and delayed cell death in ischemia-reperfusion injury.
• PARP-1 activation depletes NAD+, inhibiting both glycolysis and mitochondrial oxidative metabolism.
• Ketone bodies can sustain mitochondrial metabolism in NAD+-depleted cells, provided mitochondria remain functional.

Conclusions:

• Mitochondrial dysfunction represents a viable target for neuroprotection at later time points after cerebral ischemia.
• Ketone bodies show promise for rescuing neurons from delayed ischemic death by supporting mitochondrial function.
• Further rigorous studies are needed to define the optimal time window for ketone body administration in treating ischemic stroke.